BR112013004503A2 - antagonistas de receptor de 5ht2b - Google Patents

antagonistas de receptor de 5ht2b

Info

Publication number
BR112013004503A2
BR112013004503A2 BR112013004503A BR112013004503A BR112013004503A2 BR 112013004503 A2 BR112013004503 A2 BR 112013004503A2 BR 112013004503 A BR112013004503 A BR 112013004503A BR 112013004503 A BR112013004503 A BR 112013004503A BR 112013004503 A2 BR112013004503 A2 BR 112013004503A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
5ht2b receptor
5ht2b
medicament
prevention
Prior art date
Application number
BR112013004503A
Other languages
English (en)
Portuguese (pt)
Inventor
Johannes Wilhelmus John F Thuring
Luc August Laurentius Ver Donck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112013004503A2 publication Critical patent/BR112013004503A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013004503A 2010-09-01 2011-08-30 antagonistas de receptor de 5ht2b BR112013004503A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10174880 2010-09-01
PCT/EP2011/064906 WO2012028614A1 (en) 2010-09-01 2011-08-30 5-ht2b receptor antagonists

Publications (1)

Publication Number Publication Date
BR112013004503A2 true BR112013004503A2 (pt) 2016-06-07

Family

ID=43127285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004503A BR112013004503A2 (pt) 2010-09-01 2011-08-30 antagonistas de receptor de 5ht2b

Country Status (14)

Country Link
US (2) US8703958B2 (https=)
EP (1) EP2619180B1 (https=)
JP (1) JP5845263B2 (https=)
KR (1) KR101815123B1 (https=)
CN (1) CN103080089B (https=)
AU (1) AU2011298361B2 (https=)
BR (1) BR112013004503A2 (https=)
CA (1) CA2806647C (https=)
EA (1) EA020967B1 (https=)
ES (1) ES2525515T3 (https=)
MX (1) MX2013002409A (https=)
SG (1) SG188233A1 (https=)
WO (1) WO2012028614A1 (https=)
ZA (1) ZA201301561B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525515T3 (es) 2010-09-01 2014-12-23 Janssen Pharmaceutica, N.V. Antagonistas del receptor 5-HT2B
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点
US20170058349A1 (en) * 2014-03-04 2017-03-02 The Children's Hospital Of Philadelphia Methods for managing care of patients predisposed to progressive mitral valve diseases
CN110950843B (zh) * 2019-11-28 2022-12-27 广东东阳光药业有限公司 取代的苯酰胺衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
CN1918157B (zh) * 2004-01-07 2010-06-23 ARYx医疗有限公司 立体异构化合物及治疗胃肠道和中枢神经系统紊乱的方法
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
WO2008139152A1 (en) * 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
ES2525515T3 (es) 2010-09-01 2014-12-23 Janssen Pharmaceutica, N.V. Antagonistas del receptor 5-HT2B

Also Published As

Publication number Publication date
HK1182097A1 (zh) 2013-11-22
KR101815123B1 (ko) 2018-01-04
CN103080089A (zh) 2013-05-01
EP2619180A1 (en) 2013-07-31
AU2011298361B2 (en) 2014-03-13
US20130172386A1 (en) 2013-07-04
ES2525515T3 (es) 2014-12-23
CN103080089B (zh) 2015-09-23
ZA201301561B (en) 2014-08-27
CA2806647C (en) 2018-09-18
CA2806647A1 (en) 2012-03-08
JP2013536823A (ja) 2013-09-26
EA020967B1 (ru) 2015-03-31
US9139523B2 (en) 2015-09-22
EA201390312A1 (ru) 2013-07-30
US8703958B2 (en) 2014-04-22
SG188233A1 (en) 2013-04-30
EP2619180B1 (en) 2014-10-08
MX2013002409A (es) 2013-04-03
JP5845263B2 (ja) 2016-01-20
KR20130101503A (ko) 2013-09-13
AU2011298361A1 (en) 2013-02-14
US20140187585A1 (en) 2014-07-03
WO2012028614A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
EA201401351A1 (ru) Производные бензимидазол-пролина
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
WO2012088038A3 (en) Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CY1117792T1 (el) Ανταγωνιστες toy trpv4
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
CL2014003031A1 (es) Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
CL2008000905A1 (es) Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
HK1203932A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
TR200806298A2 (tr) Farmasötik formülasyon
WO2012088124A3 (en) Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
EA201290229A1 (ru) Производные спиролактама и их применение
BR112013004503A2 (pt) antagonistas de receptor de 5ht2b
WO2009128661A3 (ko) 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time